Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMELFBU)

Drug Name

SCY-641 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Ocular inflammation	9C61.24	Preclinical	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Discontinued Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Calcium signal-modulating cyclophilin ligand (CAML)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Alisporivir	DM83EBP	Duchenne dystrophy	8C70	Phase 3	[2]
SCY-635	DM1C9NQ	Hepatitis C virus infection	1E51.1	Phase 2	[3]
D-43787	DM0YFZ6	Allergy	4A80-4A85	Terminated	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Calcium signal-modulating cyclophilin ligand (CAML)	TTATDGJ	CAMLG_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	2011 Pipeline of SCYNEXIS.
2	DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS One. 2010 Oct 27;5(10):e13687.
3	SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro. Antimicrob Agents Chemother. 2010 Feb;54(2):660-72.
4	Anti-inflammatory effects of a cyclosporine receptor-binding compound, D-43787. J Pharmacol Exp Ther. 2002 May;301(2):738-46.